Clinical Use Of Hcg and hCGβ Determinations

References

• Pierce J G, Parsons T F. Glycoprotein hormones: Structure and function. Ann Rev Biochem 1981; 50: 465–495
   PubMed Web of Science ®Google Scholar
• Fiddes J C, Talmadge K. Structure, expression, and evolution of the genes for the human gly coprotein hormones. Rec Prog Horm Res 1984; 40: 43–78
   PubMedGoogle Scholar
• Bo M, Boime I. Identification of the transcrip tionally active genes of the chorionic gonado tropin beta gene cluster in vivo. J Biol Chem 1992; 267: 3179–3184
   PubMed Web of Science ®Google Scholar
• Ozturk M, Bellet D, Manil L, Hennen G, Frydman R, Wands J. Physiological studies of human chorionic gonadotropin (hCG), ahCG and ChCG as measured by specific monoclonal immunoradiometric assays. Endocrinol 1987; 120: 549–558
   PubMed Web of Science ®Google Scholar
• Alfthan H, Schroder J, Fraser R, Koskimies A, Halila H, Stenman U-H. Choriogonadotropin and its P subunit separated by hydrophobic-in-teraction chromatography and quantified in serum during pregnancy by time-resolved im-munofluorometric assays. Clin Chem 1988; 34: 1758–1762
   PubMed Web of Science ®Google Scholar
• Iles R K, Purkis P E, Whitehead P C, Ouver R T, Leigh I, Chard T. Expression of beta human chorionic gonadotrophin by non-trophoblastic non-endocrine ‘normal’ and malignant epithe lial cells. Br J Cancer 1990; 61: 663–6
   PubMed Web of Science ®Google Scholar
• Marcillac I, Troalen F, Bidart J-M, Ghillani P, Ribrag V, Escudier B, et al. Free human cho rionic gonadotropin fj subunit in gonadal and nongonadal neoplasms. Cancer Res 1992; 52: 3901–3907
   PubMed Web of Science ®Google Scholar
• Hoermann R, Gerbes A L, Spoettl G, Jiingst D, Mann K. Immunoreactive human chorionic go nadotropin and its free fi subunit in serum and ascites of patients with malignant rumors. Cancer Res 1992; 52: 1520–1524
   PubMed Web of Science ®Google Scholar
• Alfthan H, Haglund C, Roberts P, Stenman U-H. Elevation of free P subunit of human chorio gonadotropin and core P fragment of human choriogonadotropin in serum and urine of pa tients with malignant pancreatic and biliary disease. Cancer Res 1992; 52: 4628–4633
   PubMed Web of Science ®Google Scholar
• Stenman U-H, Alfthan H, Ranta T, Vartiainen E, Jalkanen J, Seppala M. Serum levels of human chorionic gonadotropin in nonpregnant women and men are modulated by gonado tropin releasing hormone and sex steroids. J Clin Endocrinol Metab 1987; 64: 730–736
   PubMed Web of Science ®Google Scholar
• Odell W D, Griffin J. Pulsatile secretion of human chorionic gonadotropin in normal adults. N Engl J Med 1987; 317: 1688–1691
   PubMed Web of Science ®Google Scholar
• Hoermann R, Spoettl G, Moncayo R, Mann K. Evidence for the presence of human chorionic gonadotropin (hCG) and free beta-subunit of hCG in the human pituitary. J Clin Endocrinol Metab 1990; 71: 179–86
   PubMed Web of Science ®Google Scholar
• Braunstein G D, Rasor J, Adler D, Danzer H, Wade M E. Serum human chorionic gonado tropin levels throughout normal pregnancy. Am J Obstet Gynecol 1976; 15: 678–681
   Google Scholar
• Braunstein G D, Karow W G, Gentry W C, Rasor J, Wade M E. First-trimester chorionic gonado tropin measurements as an aid in the diagnosis of early pregnancy disorders. Am J Obstet Gynecol 1978; 131: 25–32
   PubMed Web of Science ®Google Scholar
• Cartwright P S, DiPietro D L. Ectopic pregnancy: changes in serum human chorionic go nadotropin concentration. Obstet Gynecol 1984; 63: 76–80
   PubMed Web of Science ®Google Scholar
• Kadar N, Caldwell B V, Romero R. A method of screening for ectopic pregnancy and its indica tions. Obstet Gynecol 1981; 58: 162–6
   PubMed Web of Science ®Google Scholar
• Cole L A, Restrepo-Candelo H, Lavy G, Decherney A. hCG free P-subunit an early marker of outcome of in vitro fertilization clinical preg nancies. J Clin Endocrinol Metab 1987; 64: 1328–30
   PubMed Web of Science ®Google Scholar
• Crossley J A, Aitken D A, Connor J M. Prenatal screening for chromosome abnormalities using maternal serum chorionic gonadotrophin, alpha-fetoprotein, and age. Prenat Diagn 1991; 11: 83–101
   PubMed Web of Science ®Google Scholar
• MacDonald M L, Wagner R M, Slotnick R N. Sen sitivity and specificity of screening for Down syndrome with alpha-fetoprotein, hCG, uncon jugated estriol, and maternal age [published erratum appears in Obstet Gynecol 1991 May;77(3):462] [see comments]. Obstet Gynecol 1991; 77: 63–8
   PubMed Web of Science ®Google Scholar
• Spencer K, Coombes E, Mallard A, Milford Ward A. Free beta human choriogonadotropin in Down's syndrome screening: a multicenter study of its role compared with other biochemi cal markers. Arm Clin Biochem 1992; 29: 505–18
   Google Scholar
• Soper J. Gestational trophoblastic neoplasia. Curr Opin Obstet Gynecol 1990; 2: 92–7
   PubMedGoogle Scholar
• Bates S E. Clinical applications of serum tumor markers. Ann Int Med 1991; 115: 623–38
   PubMed Web of Science ®Google Scholar
• Bagshawe K D. Choriocarcinoma. A model for tumor markers. Acta Oncol 1992; 31: 99–106
   PubMed Web of Science ®Google Scholar
• Miller D S, Lurain J R. Classification and staging of gestational trophoblastic tumors. Obstet Gynecol Clin North Am 1988; 15: 477–90
   PubMed Web of Science ®Google Scholar
• Berkowitz R S, Goldstein D P. Diagnosis and management of the primary hydatidiform mole. Obstet Gynecol Clin North Am 1988; 15: 491–503
   PubMed Web of Science ®Google Scholar
• Berkowitz R, Ozturk M, Goldstein D, Bernstein M, Hill L, Wands J R. Human chorionic gonado tropin and free subunits' serum levels in pa tients with partial and complete hydatidiform moles. Obstet Gynecol 1989; 74: 212–6
   PubMed Web of Science ®Google Scholar
• Berkowitz R S, Goldstein D P, Bernstein M R. Natural history of partial molar pregnancy. Ob stet Gynecol 1985; 66: 677–81
   PubMed Web of Science ®Google Scholar
• Rice L, Berkowitz R, Lage J, Goldstein D, Bern stein M. Persistent gestational trophoblastic tumor after partial hydatidiform mole. Gynecol Oncol 1990; 36: 358–62
   PubMed Web of Science ®Google Scholar
• Carl J. Drug-resistance patterns assessed from tumor marker analysis. J Natl Cancer Inst 1989; 81: 1631–9
   PubMedGoogle Scholar
• Ozturk M, Berkowitz R, Goldstein D, Belief D, Wands J R. Differential production of human chorionic gonadotropin and free subunits in gestational trophoblastic disease. Am J Obstet Gynecol 1988; 158: 193–8
   PubMed Web of Science ®Google Scholar
• Ozturk M. Human chorionic gonadotropin, its free subunits and gestational trophoblastic dis ease. J Reprod Med 1991; 36: 21–6
   PubMed Web of Science ®Google Scholar
• Rinker A D, Tietz N W. Beta-hCG vs intact hCG assays in the detection of trophoblastic disease. Clin Chem 1989; 35: 1799–800
   PubMed Web of Science ®Google Scholar
• Bartlett N L, Freiha F S, Torti F M. Serum markers in germ cell neoplasms. Hematol Oncol Clin North Am 1991; 5: 1245–60
   PubMed Web of Science ®Google Scholar
• Hussa R O. Human chorionic gonadotropin, a clinical marker: review of its biosynthesis. Li-gand Review 1981; 3: 6–44
   Google Scholar
• Klepp O. Serum tumour markers in testicular and extragonadal germ cell malignancies. Scand J Clin Lab Invest Suppl 1991; 206: 28–41
   PubMedGoogle Scholar
• Lange P H, Nochomovitz L E, Rosai J, Fraley E E, Kennedy B J, Bosl G, et al. Serum alpha-fetopro-tein and human chorionic gonadotropin in pa tients with seminoma. J Urol 1980; 124: 472–8
   PubMed Web of Science ®Google Scholar
• Mann K, Siddle K. Evidence for free beta-sub-unit secretion in so-called human chorionic go-nadotropin-positive seminoma. Cancer 1988; 62: 2378–82
   PubMed Web of Science ®Google Scholar
• Thomas G, Jones W, VanOosterom A K T. Consensus statement on the investigation and management of testicular seminoma 1989. Prog Clin Biol Res 1990; 357: 285–94
   PubMedGoogle Scholar
• Dieckmann K P, Due W, Bauer H W. Seminoma testis with elevated serum beta-HCG–a ca tegory of germ-cell cancer between seminoma and nonseminoma. Int Urol Nephrol 1989; 21: 175–84
   PubMedGoogle Scholar
• Anderson T, Waldmann T, Javadpour N, Glat-stein E. Testicular germ cell neoplasms: recent advances in diagnosis and therapy. Ann Intern Med 1979; 90: 373–85
   PubMed Web of Science ®Google Scholar
• Bosl G J, Lange P H, Fraley E E, Goldman A, Nochomovitz L E, Rosai J, et al. Human cho rionic gonadotropin and alphafetoprotein in the staging of nonseminomatous testicular cancer. Cancer 1981; 47: 328–32
   PubMed Web of Science ®Google Scholar
• Murphy P, Johnson D H. Staging and prognos tic factors in nonseminomatous testicular cancer. Hematol Oncol Clin North Am 1991; 5: 1233–43
   PubMed Web of Science ®Google Scholar
• Aass N, Klepp O, Cavallin-Stahl E, Dahl O, Wicklund H, Unsgaard B, et al. Prognostic fac tors in unselected patients with nonseminoma tous metastatic testicular cancer: a multicenter experience. J Clin Oncol 1991; 9: 818–26
   PubMed Web of Science ®Google Scholar
• Jensen J L, Venner P M. Predictive factors for outcome in treatment of metastatic nonsemino matous germ cell tumors. Urology 1992; 39: 237–42
   PubMed Web of Science ®Google Scholar
• Mead G M, Stenning S P, Parkinson M C, Hor-wich A, Fossa S D, Wilkinson P M, et al. The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicu lar Tumour Working Party. J Clin Oncol 1992; 10: 85–94
   PubMed Web of Science ®Google Scholar
• Sesterhenn I A, Weiss R B, Mostofi F K, Stablein D M, Rowland R G, Falkson G, et al. Prognosis and other clinical correlates of pathologic re view in stage I and II testicular carcinoma: a report from the Testicular Cancer Intergroup Study. J Clin Oncol 1992; 10: 69–78
   PubMed Web of Science ®Google Scholar
• Geller N, Bosl G, Chan E. Prognostic factors for relapse after complete response in patients with metastatic germ cell tumors. Cancer 1989; 63: 440–5
   PubMed Web of Science ®Google Scholar
• Droz J, Kramar A. Prognostic fac tors in advanced nonseminomatous testicular cancer. A multivariate logistic regression ana lysis. Cancer 1988; 62: 564–8
   PubMed Web of Science ®Google Scholar
• Butcher D N, Gregory W M, Gunter P A, Masters J R, Parkinson M C. The biological and clinical significance of HCG-containing cells in semi noma. Br J Cancer 1985; 51: 473–8
   PubMed Web of Science ®Google Scholar
• Sailer B, Clara R, Spottl G, Siddle K, Mann K. Testicular cancer secretes intact human chorio gonadotropin (hCG) and its free beta-subunit: evidence that hCG (+hCG-beta) assays are the most reliable in diagnosis and follow-up [see comments]. Clin Chem 1990; 36: 234–9
   PubMed Web of Science ®Google Scholar
• Madersbacher S, Klieber R, Mann K, Marth C, Tabarelli M, Wick G, Berger P. Free alpha-sub-unit, free beta-subunit of human chorionic go nadotropin (hCG), and intact hCG in sera of healthy individuals and testicular cancer pa tients. Clin Chem 1992; 38: 370–6
   PubMed Web of Science ®Google Scholar
• Mann K, Bechtel U, Gokel J, Siddle K. Das hCG-positive Seminom immunhistologische und serologische Befunde. Diag-nostik und Therapie von Hodentumoren. Ber lin, W Schmoll. Springer, Heidelberg 1988; 421–6
   Google Scholar
• Sailer B, Mumperow E, Dettmann Rea, Spotte G, Hartmann M, Bussar-Maatz R. Weissbach : Mann K. HCG/HCG-beta immunoactivity in testicular vein samples from patients with pure seminoma. Exp Clin Endocrinol 1993; 101(Suppl 1)16
   Google Scholar
• Mumperow E, Hartmann M. Spermatic cord beta-human chorionic gonadotropin levels in seminoma and their clinical implications. J Urol 1992; 147: 1041–3
   PubMed Web of Science ®Google Scholar
• Seckl M J, Rustin G J, Bagshawe K D. Frequency of serum tumour marker monitoring in patients with non-seminomatous germ cell tumours [see comments]. Br J Cancer 1990; 61: 916–8
   PubMed Web of Science ®Google Scholar
• Toner G C, Geller N L, Tan C, Nisselbaum J, Bosl G J. Serum tumor marker half-life during che motherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors. Cancer Res 1990; 50: 5904–10
   PubMed Web of Science ®Google Scholar
• Horwich A, Peckham M J. Transient tumor mar ker elevation following chemotherapy for germ cell tumors of the testis. Cancer Treat Rep 1986; 70: 1329–31
   PubMedGoogle Scholar
• Braunstein G D, Vairukaitis J L, Carbone P P, Ross G T. Ectopic production of human cho rionic gonadotrophin by neoplasms. Ann Int Med 1973; 78: 39–45
   PubMed Web of Science ®Google Scholar
• Kuida C A, Braunstein G D, Shintaku P, Said J W. Human chorionic gonadotropin expression in lung, breast, and renal carcinomas. Arch Pathol Lab Med 1988; 112: 282–5
   PubMed Web of Science ®Google Scholar
• Senba M., Watanabe M. Ectopic production of beta-subunit of human chorionic gonadotropin in malignant lymphoma. Zentralbl Pathol 1991; 137: 402–4
   PubMedGoogle Scholar
• Oberg K, Wide L. hCG and hCG subunits as tumour markers in patients with endcocrine pancreatic tumours and carcinoids. Acta Endo crinol 1981; 98: 256–260
   PubMed Web of Science ®Google Scholar
• Bardram L, Agner T, Hagen C. Levels of alpha-subunits of gonadotropins can be increased in Zollinger-Ellison syndrome, both in patients with malignant tumours and with apparently benign disease. Acta Endocrinol Copenh 1988; 118: 135–41
   PubMedGoogle Scholar
• Bordi C, Pilato F P, D'Adda T. Comparative study of seven neuroendocrine markers in pan creatic endocrine tumours. Virchows Arch A Pathol Anat Histopathol 1988; 413: 387–98
   PubMedGoogle Scholar
• Ilies R K, Chard T. Human chorionic gonado tropin expression by bladder cancers: biology and clinical potential. J Urol 1991; 145: 453–8
   PubMed Web of Science ®Google Scholar